Gene therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gene therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote ()	6/26/2000 6:55:00 AM
From: nigel bates	of 319

Monday June 26, 11:25 AM Shares in British biotechnology group Oxford Biomedica (LSE: OXB.L - news) jumped 6.5 pence, or 11.7 percent, to a two-month high of 62 pence after it announced positive results from trials of its LentiVector system for transferring genes into the brain and other parts of the nervous system. The LentiVector system is based on a horse virus called Equine Infectious Anaemia Virus (EIAV). "The Company has engineered the virus so that it picks up therapeutic genes and delivers them to human cells. The EIAV-based vector has been constructed so that, unlike many other gene therapy vectors, it does not transfer any viral genes to the patient's cells," Oxford Biomedica said.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next